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CVD: Cardiovascular diseases 
FC: Flow cytometry 
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FISH: Fluorescence in situ hybridization 
FSC: Forward scatter detector 
FVOO: phenolic compounds-enriched virgin olive oil containing 500 mg phenolic compounds/kg, from olive oil  
FVOOT:  phenolic compounds-enriched virgin olive oil containing a mixture of 500 mg phenolic 
compounds/kg, from olive oil and thyme, 1:1. 
MD: Mediterranean diet 
PC: Phenolic compounds 
PCA: Protocatechuic acid 
SCFA: Short chain fatty acids 
SSC: Side scatter detector 





Purpose To investigate the effect of virgin olive oil phenolic compounds (PC) alone or in combination with 2 
thyme PC on blood lipid profile from hypercholesterolemic humans, and whether the changes generated are 3 
related with changes in gut microbiota populations and activities.  4 
Methods A randomized, controlled, double-blind, crossover human trial (n=12) was carried out. Participants 5 
ingested 25 mL/day for 3 weeks, preceded by 2-week washout periods, of three raw virgin olive oils differing in 6 
the concentration and origin of PC: (1) a virgin olive oil naturally containing 80 mg PC/kg, (VOO), (2) a PC-7 
enriched virgin olive oil containing 500 mg PC/kg, from OO (FVOO), and (3) a PC-enriched virgin olive oil 8 
containing a mixture of 500 mg PC/kg from OO and thyme, 1:1 (FVOOT). Blood lipid values and fecal 9 
quantitative changes in microbial populations, short chain fatty acids, cholesterol microbial metabolites, bile 10 
acids, and phenolic metabolites were analyzed. 11 
Results FVOOT decreased seric ox-LDL concentrations compared with pre-FVOOT, and increased numbers of 12 
bifidobacteria and the levels of the phenolic metabolite protocatechuic acid compared to VOO (P<0.05). FVOO 13 
did not lead to changes in blood lipid profile nor quantitative changes in the microbial populations analyzed, but 14 
increased the coprostanone compared to FVOOT (P<0.05), and the levels of the fecal hydroxytyrosol and 15 
dihydroxyphenilacetic acids, compared with pre-intervention values and to VOO respectively (P<0.05). 16 
Conclusion The ingestion of a PC-enriched virgin olive oil, containing a mixture of olive oil and thyme PC for 17 
three weeks, decreases blood ox-LDL in hypercholesterolemic humans. This cardio-protective effect could be 18 
mediated by the increases in populations of bifidobacteria together with increases in anti-oxidant PC microbial 19 
metabolites.  20 
 21 
Introduction 22 
Adherence to the Mediterranean Diet (MD) has shown to be cardio-protective [1]. Consumption of virgin olive 23 
oil (OO), the main fat of the MD, has demonstrated a relevant influence on its beneficial effects [2]. Besides 24 
oleic acid, the phenolic fraction of virgin OO also contributes to the health effects associated with virgin OO 25 
consumption [3]. Its antioxidant and anti-inflammatory activities, acting as pathway and gene expression 26 
modulators [4], may explain such health properties. However, the mechanisms by which virgin olive oil PC 27 
influence cardiovascular disease (CVD) risk factors are not fully understood. Recent insights indicate that gut 28 
microbiota plays an important role in CVD, and represents a realistic therapeutic target [5]. Some of reported gut 29 
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microbiota-related mechanisms by which gut bacteria could  influence CVD risk factors such as the presence of 30 
abnormal levels of blood lipids [6], could be one or a combination of the following: (1) involvement in 31 
cholesterol synthesis through generation of short chain fatty acids (SCFA) which are generated from microbial 32 
fermentation of undigested substrates, either increasing blood total cholesterol (i.e., acetic) or  decreasing it (i.e., 33 
propionic, butyric) [7]; (2) reduction of the amount of cholesterol available for re-absorption from the intestine 34 
by either transforming gut cholesterol to insoluble metabolites and, thereby, its uptake from the gut [8] and/or  35 
by incorporating cholesterol into the microbial cellular membrane [9,10]; (3) deconjugation of  bile salts in the 36 
gut, generating insoluble primary bile acids which are excreted in feces [11], which lead to cholesterol 37 
expenditure in the liver in order to synthesize new bile acids; (4) generation of bioactive metabolites in the gut 38 
with cardio-protective properties. Diet appears to critically in influence both the relative abundance of different 39 
gut microorganisms and their metabolic output. In this sense, high intake of PC from different sources appears to 40 
regulate some CVD risk factors [12, 13], through the modulation of microbial populations and activities [14], as 41 
many plants PC are not totally absorbed and become available for microbiota utilization as an energy source 42 
which has an impact on nutrient bioavailability and host metabolism. Regarding virgin olive oil PC, recent 43 
studies have demonstrated that they are able to reach the gut, being transformed by gut microbiota [15].  It has 44 
also been shown that the bioaccesibility of virgin olive oil PC can be increased by combining virgin olive oil PC 45 
with other PC sources (i.e, thyme) [16, 17]. Since the interaction of virgin olive oil phenolic compounds with gut 46 
microbiota and its involvement in CVD risk remains to be elucidated, the aim of our study was to investigate the 47 
effect of a sustained consumption of virgin olive oil PC, alone or in combination with thyme PC on blood lipid 48 
levels in hypercholesterolemic subjects, and whether this effect is mediated by gut microbiota-related 49 
mechanisms. 50 
 51 
Material and methods. 52 
Study subjects and design 53 
The present study included a subsample of 12 hypercholesterolemic (total cholesterol>200 mg/dL) adults (5 54 
females and 7 males) aged 46–67 y from the VOHF (Virgin Olive Oil and HDL Functionality) study. The VOHF 55 
study was a randomized, controlled, double-blind, crossover clinical trial with 33 hypercholesterolemic 56 
volunteers, aged 35 to 80 year. Exclusion criteria included the following: BMI>35 Kg/m2, smokers, athletes 57 
with high physical activity (>3000 Kcal/day), diabetes, multiple allergies, intestinal diseases, or other disease or 58 
condition that would worsen adherence to the measurements or treatments. The study was conducted at IMIM- 59 
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Hospital del Mar Medical Research Institute (Spain) from April 2012 to September 2012. Participants ingested 60 
25 mL/day for 3 weeks, preceded by 2-week washout periods, of three raw virgin olive oils differing in the 61 
concentration and origin of phenolic compounds (PC):  (1) a virgin olive oil naturally containing 80 mg PC/kg 62 
(VOO), (2) a PC-enriched virgin olive oil containing 500 mg PC/kg, from olive oil (FVOO), and (3) a PC-63 
enriched virgin olive oil containing a mixture of 500 mg PC/kg from olive oil and thyme, 1:1 (FVOOT).  64 
Participants were randomized to one of 3 orders of administration (Order 1: FVOO, FVOOT and VOO, Order 2: 65 
FVOOT, VOO and FVOO, Order 3: VOO, FVOO and FVOOT). Elaboration of PC enriched olive oils (i.e. 66 
FVOO and FVOOT) is described by Rubió et al [18]. Full phenolic composition of the three oils is presented in 67 
Table 1. The random allocation sequence was generated by a statistician, participant enrolment was carried out 68 
by a researcher, and participants’ assignment to interventions according to the random sequence was done by a 69 
physician. Due to the fact that all participants received each one of the three oils, restrictions such as blocking 70 
were unnecessary. In order to avoid an excessive intake of PC other than those provided by the intervention’s 71 
oils, participants were asked to limit the consumption of rich-polyphenol food and dietary data was recorded by 72 
3-day dietary record at baseline and before and after each intervention period. The corresponding 25 mL bottles 73 
of the corresponding oil for each day of consumption were provided to the participants at the beginning of each 74 
intervention period. The participants were instructed to return the bottles in order to register the amount of the 75 
intervention oil consumed. Subjects with less than 80% of treatment adherence (≥ 5 full oil containers returned) 76 
were considered non-compliant for the dietary intervention. Blood at fasting state (of at least 10 hours) and fecal 77 
samples were collected before and after each intervention period. All participants provided written informed 78 
consent, and the local institutional ethics committees approved the protocol (CEIC-IMAS 2009/3347/I). The trial 79 
was registered with the International Standard Randomized Controlled Trial register (www.controlled-trials.com; 80 
ISRCTN77500181).  81 
Dietary adherence 82 
Twenty-four-hour urine was collected at the start of the study and before and after each treatment. Urine samples 83 
were stored at –80°C prior to use. We measured urinary hydroxytyrosol sulfate and thymol sulfate as biomarkers 84 
of adherence to the type of OO ingested in urine by ultra-HPLC-ESI-MS/MS [19]. A 3-day dietary record was 85 
administered to the participants at baseline and before and after each intervention period. A nutritionist 86 
personally advised participants to replace all types of habitually consumed raw fats with the OOs, and to limit 87 
their polyphenol-rich food consumption. 88 
Serum lipid profile analysis 89 
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Total and HDL cholesterol, and triglyceride concentrations were measured by using standard enzymatic 90 
automated methods. When triglyceride concentrations were <300 mg/dL, LDL cholesterol was calculated by 91 
using Friedewald's formula. Oxidized LDL was determined with an ELISA procedure that employed the murine 92 
monoclonal antibody mAb-4E65 (Mercodia AB). 93 
 94 
Fecal sample collection and pre-analytical treatment 95 
For fecal collection, participants were given a set containing: a sterile pot, a w-zip plastic pouch (AN0010W, 96 
Oxoid, Basingstoke, UK), two anaerobic sachets (AnaeroGen Compact AN0025, Oxoid), and one anaerobic 97 
indicator (BR0055, Oxoid). Freshly voided fecal samples were collected by the volunteers in the sterile pot and 98 
kept under anaerobic conditions by introducing them into the plastic pouch, together with the anaerobic sachets 99 
and the anaerobic indicator. In order to avoid changes in microbial populations, fecal samples were brought to 100 
the laboratory within 2 hours after defecation. 101 
For quantitative analysis of gut microbiota, feces were diluted with sterile 0.1 M, pH 7.0, phosphate buffered 102 
saline (PBS, Sigma-Aldrich Co. LLC., St. Louis, United States) (1:10,w:w), mixed in a Stomacher 400 (Seward, 103 
Thetford, Norfolk, UK) for 2 min and fecal slurries homogenized. After centrifugation (1300 g, 3 min), hexane 104 
(Sigma-Aldrich, UK) was added to the fecal homogenate supernatant (4:1, v:v), mixed by inversion for 2 105 
minutes and removed after centrifugation (15500 g, 5 min) and evaporation. Pellets were washed in 1mL of 106 
filtered sterile PBS and centrifuged (15500 g, 5 min). Afterwards, pellets were then diluted in 375 µL of PBS 107 
and fixed in ice-cold 4% (w:v) paraformaldehyde (PFA) (1:4, v:v) for 4 h at 4ºC. PFA was discarded after 108 
centrifugation (15500 g, 5 min) and washing twice in 1mL of sterile PBS. Cells containing pellets were 109 
homogenized in 150 µL of sterile PBS plus 150 µL of ethanol and stored at -20ºC until analysis. 110 
For the rest of the fecal analytical determinations (phenolic metabolites, short chain fatty acids (SCFA), 111 
cholesterol microbial metabolites and bile acids) fresh feces were immediately frozen at -80ºC, freeze dried, 112 
weighed to determine the percentage of humidity, milled, desiccated, and stored at -20ºC.  113 
 114 
Quantification of fecal microbiota by FISH-FC  115 
Bacterial hybridizations were based on the method described by Massot-Cladera et al [20] with some 116 
modifications. Briefly, 5 µL of fixed cell suspensions were centrifuged at 15500 g for 5 minutes. 30 µL of a 117 
mixture (1:10, v:v) of  synthetic oligonucleotide probes (50 ng/µL) targeting specific diagnostic regions of 16S 118 
rRNA and labeled with the fluorescent Cy3 dye (Ato291 [21], Bac303 [26], Bif164 [27], Chis150 [22], Erec482 119 
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[22], Fprau645 [23], Lab158 [24], Prop853 [25] and Rrec584 [25]), plus preheated hybridization buffer (0.9 M 120 
NaCl, 20 mM Tris–HCl pH 8, 0.01% sodium dodecyl sulfate), were added to the pellets, homogenized and 121 
incubated in a thermocycler for 4 hours at each specific probe hybridization temperature, in the dark. After 122 
hybridization, samples were washed by adding 2 mL of a mixture of preheated wash buffer (0.9 M NaCl, 20 mM 123 
Tris–HCl pH 8) where 0.04% of 6-diamidino-2-phenylindole dihydrochloride (50 ng/ µL; Sigma-Aldrich) was 124 
added,  for 15 minutes at each specific probe hybridization temperature in the dark. Washed samples were then 125 
centrifuged at 15500 g for 5 minutes. Pellets were homogenized in 200 µL of PBS solution and kept in the dark 126 
at 4ºC overnight. Immediately before the flow cytometry analysis, 30 µL of Commercial Flow CheckTM 127 
Fluorospheres (Beckman Coulter, Inc. FL, USA) were added to the samples in order to calculate total counts of 128 
bacteria. 129 
A LSRFortessa flow cytometer (Becton Dickinson, New Jersey, United States) was used for bacteria 130 
quantifications. The flow cytometer parameters were adjusted for bacterial counts. Bacteria morphology was 131 
selected according to their FSC/SSC signal. For this purpose, selected bacteria (Leibniz-Institut DSMZ 132 
collection, Germany) representative of each bacterial group hybridized by each probe (Collinsella aerofaciens 133 
for Ato291; Bacteroides caccae for Bac303; Bifidobacterium bifidum for Bif164; Clostridium acetobutylicum for 134 
Chis150; Clostridium saccharolyticum for Erec482; Faecalibacterium praustnizii for Fprau645; Lactobacillus 135 
plantarum for Lab158; Megasphaera elsdenii for Prop853; Roseburia intestinalis for Rrec584) were grown, 136 
fixed and hybridized as described above. Bacteria hybridized with Cy3-labeled probes were detected using a 137 
yellow and green laser (561 nm filter), and DAPI bacteria stained DNA was detected using violet one (405 nm 138 
filter). Both lasers worked at 50 mW power. An acquisition gate of 2500 fluorospheres was established. Analysis 139 
was performed using the FACSDiva software version 6.1.2 (Becton Dickinson). Microbiota composition results 140 
were expressed as the log fecal cells/g dry feces for each sample. 141 
 142 
Analysis of SCFA  143 
For the analysis of SCFA, freeze-dried samples were diluted 10-fold with milliQ water and centrifuged, first at 144 
1800 g for 5 minutes and afterwards at 8784 g for 4 minutes at 4ºC. Supernatants were filtered through a 0.22 145 
µm filter and subjected to GC analysis (Agilent 7890A Series, Santa Clara,  EEUU) using a capillary BP-146 
21column (SGE, Cromlab SL, Barcelona, Spain) (30 m, 0.25 mm, 0.25 μm) coupled to a flame ionization 147 
detector (FID) [28]. 4-methyl valeric acid (Sigma-Aldrich) was used as internal standard. Concentrations of 148 
SCFA were calculated from calibration curves using standard solutions with known concentrations of acetic, 149 
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propionic, butyric, isobutyric, isovaleric and valeric acids (Sigma-Aldrich). Results were expressed as µmol/g 150 
dry feces. 151 
 152 
Analysis of cholesterol microbial metabolites and bile acids. 153 
Freeze dried milled feces were diluted in milliQ water (0.1:4, m:v) and homogenized. A volume of 400 µL of 154 
fecal homogenate was used for the extractions, following the method described Santas et al.  [29] with some 155 
modifications. For cholesterol and its microbial metabolites, sterol mixtures were prepared as calibrators. 5-α-156 
cholestane (10 g, Sigma-Aldrich) was used as internal standard. Samples were hydrolyzed with 1 mL of NaOH 157 
(1N, in ethanol) for 1h at 70ºC. After cooling the tubes at room temperature, 0.5 mL of water was added and 158 
tubes were sonicated for 5 minutes. After 2 extractions with cyclohexane (3 mL each), mixed organic phases 159 
were evaporated under a 15 psi nitrogen stream at 30ºC.  160 
For bile acid analysis, bile acid mixtures were prepared. 5-β-cholanic acid (Sigma-Aldrich) was used as internal 161 
standard. Samples were hydrolyzed with 1 mL NaOH 1N at 70ºC for 1h. After cooling the tubes, liquid-liquid 162 
extraction with 3 mL of tert-butylmethyl ether was done twice. Organic phases were further cleaned with 2 mL 163 
of NaCl 1%. The organic phase was evaporated under a 15 psi nitrogen stream at 30ºC. 164 
Derivatization of both sterols and bile acids was carried out by addition of 50 µL of N-methyl-165 
bis(trifluoroacetamide)/NH4I/2-mercaptoethanol (1000/2/6) (Macherey-Nagel, Düren, Germany) and dry heated 166 
at 60ºC for 20 minutes. A gas chromatograph (6890 N; Agilent Technologies, Wilmington, DA, USA) equipped 167 
with a mass selective detector (5973 Network, AT) and an autosampler injector (7683 series, AT) was used for 168 
analysis and performed in a 100% methylsiloxane column (Agilent Ultra 1) in all cases. After derivatization, 169 
both neutral sterols and bile acids were quantified with their respective standards, expressed as µmol/g and 170 
µmol/10g dry feces, respectively. 171 
 172 
Analysis of phenolic microbial metabolites 173 
For PC metabolite analysis, freeze-dried feces (0.1 g) were mixed with 1 mL of milli-Q water. Samples were 174 
shaken for 30 min and centrifuged (13200 g, 10 min, 4ºC). Supernatants were centrifuged (13200 g, 10 min, 4ºC) 175 
and filtered through a membrane (0.22 µm pore size) and transferred to chromatographic vials. PC metabolites 176 
analysis was performed as previously described [15,17] and were quantified using the calibration curve of their 177 
respective standard. PC metabolites concentration results were expressed as µmol/100g dry feces.  178 
Sample size 179 
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The sample size for this study was calculated with the free software GRANMO 180 
(http://www.imim.cat/ofertadeserveis/software-public/granmo/) by selecteing 80% power (5% α level) to detect 181 
a 0.4 log10/g dry feces difference among treatments in the primary outcome variable (Bif164 counts/g of dry 182 
feces), with a standard deviation of treatment differences less than 0.48 (log10 scale). 183 
 184 
Statistical analysis 185 
Normality of continuous variables was assessed with normal probability plots and the Shapiro-Wilk test. Non-186 
normally distributed variables were log transformed previous to the analysis. Paired t test was used for intra-187 
intervention comparisons. Adjusted general linear mixed models with a period-by-treatment interaction term 188 
were used for inter-intervention comparisons, given results as adjusted means. P≤0.05 was considered 189 
significant. Statistical analyses were performed with an R software version 2.11.1 (R Development Core Team, 190 




Urine compliance markers (hydroxytyrosol sulfate and thymol sulfate) indicated good adherence to the oil 195 
interventions (Supplementary table 1). The three intervention oils were well tolerated by all participants and no 196 
adverse events were reported. 197 
 198 
Blood lipid profile 199 
Serum concentrations of cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol) did not present any 200 
statistical change with any of the dietary interventions (data not shown). Oxidized LDL concentrations decreased 201 
after FVOOT intervention compared to pre-FVOOT values (P=0.049) (Figure 1) 202 
 203 
Analysis of quantitative changes in gut microbiota 204 
Quantitative changes in fecal microbiota before and after interventions are presented in table 2. Consumption of 205 
virgin olive oil PC alone (FVOO) did not have a significant effect on bacterial counts.  Only a decrease in 206 
numbers of Clostridium cluster IX (Prop853) compared to VOO intervention was observed, although this 207 
decrease did not reach statistical significance (P= 0.066). When virgin olive oil PC were combined with thyme 208 
PC (FVOOT) the numbers of  the bacterial groups hybridized by Bif164 probe (most Bifidobacterium spp and 209 
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Parascardovia denticolens) significantly increased compared to VOO (P= 0.044). PC combination also 210 
increased the numbers of Roseburia-Eubacterium rectale group (Rrec584 probe) compared to FVOO 211 
intervention but this increment did not reach statistical significance (P= 0.085).  212 
 213 
Analysis of changes in microbial activities. 214 
The analysis of the main SCFA generated by gut microbial fermentation (acetic, butyric, propionic and branched 215 
acids) did not show significant changes with any of the interventions (table 3). Their relative amounts remained 216 
constant along the trial irrespective of the intervention (54-58%, 15-18%, 16-18% and 8-10%, respectively). 217 
From the fecal concentrations of cholesterol and microbial cholesterol metabolites (coprostanol, coprostanone, 218 
cholestanone) analysed, only coprostanone changed with the dietary interventions, by increasing with FVOO 219 
compared to FVOOT (P= 0.028) (table 3). Changes in concentrations of fecal bile acids after dietary 220 
interventions did not reach statistical significance (table 3). However, the relative proportion of isolithocholic 221 
acid, referred to the total of fecal bile acids analyzed, decreased after FVOO compared with pre-FVOO (from 222 
6.29 % CI (5.81, 6.80) to 3.47 % CI (3.20, 3.75); P=0.020). 223 
The analysis of fecal phenolic metabolites is presented in table 4. Hydroxytyrosol increased and tended to 224 
increase after FVOO (P=0.034) and FVOOT (P=0.064) respectively. FVOO increased dihydroxyphenylacetic 225 
acid compared to VOO (P=0.014).  Protocatechuic acid increased with FVOOT compared to VOO (P=0.003). 226 




The aim of this study was to elucidate whether the possible cardio-protective effects of a sustained consumption 231 
of virgin olive oil phenolic compounds (PC) alone or in combination with thyme PC are mediated by changes in 232 
gut microbiota populations and metabolic activities, in hypercholesterolemic humans.  233 
The combination of olive oil and thyme PC exerted a cardio-protective effect, by decreasing blood levels of ox-234 
LDL. The anti-oxidant activity of some microbial phenolic metabolites such as hydroxytyrosol and 235 
protocatechuic acid, generated after gut microbial fermentation of phenolic compounds contained in FVOOT, 236 
could be involved in the observed effects on LDL. After oxidation, LDL becomes more toxic and plays a 237 
primary role in the development and progression of atherosclerosis [30]. It has been reported that oxidation of 238 
LDL decreases with increasing phenolic content of olive oil [3, 31,32]. In fact, the European Food Safety 239 
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Authority approved a claim concerning the benefits of olive oil polyphenols for the protection of LDL from 240 
oxidation [33]  241 
We observed quantitative significant changes in gut microbiota only when virgin olive oil PC were ingested 242 
together with thyme PC, by increasing Bifidobacterium group numbers. The gut microbial usage of virgin olive 243 
oil and thyme PC has been recently reported in a linear non controlled study, by Mosele et al. [15,17]. They 244 
observed the generation of PC metabolites after microbial transformation of virgin olive oil and thyme parental 245 
PC, concluding that some of the investigated parental PC were able to reach the gut, afterwards being 246 
transformed by gut microbiota. Increases in gut bifidobacteria have been reported with other sources of phenolic 247 
compounds such as wine [34], wild blueberry [35], pomegranate peel [36] and cocoa [7]. However, this is the 248 
first time that a potential bifidogenic effect is reported for a combination of virgin olive oil and thyme PC. Since 249 
prebiotic is defined as “a selectively fermented ingredient that allows specific changes, both in the composition 250 
and/or activity in the gastrointestinal microflora that confers benefits upon host well-being and health” [37] a 251 
potential prebiotic activity of the combination of PC in FVOOT is suggested, and should be further investigated.  252 
Since recent studies in animals and humans have shown improvements in blood lipid profile with the ingestion 253 
of bifidobacteria and lactobacilli mixtures [38, 39], the increase in Bifidobacterium could be responsible at least 254 
in part for the decrease in oxLDL levels observed with the ingestion of FVOOT.  255 
Regarding blood cholesterol levels, hardly any effects were observed on the cholesterol lowering mechanisms 256 
investigated. This is in accordance with the lack of changes reported in blood cholesterol levels. First, we 257 
investigated whether microbial usage of PC was able to generate changes in SCFA production, related to 258 
cholesterol synthesis.  In our study, neither fecal amounts of acetic, propionic and butyric acids nor their relative 259 
amounts changed with any of the interventions. Grapefruit PC have been shown to increase amounts of SCFA in 260 
rats [40] whereas black tea and red wine PC decreased them in vitro [41].  The lack of effects observed in our 261 
study could be due to the fact that, contrary to what occurs in an in vitro system, SCFA generated are also 262 
absorbed in vivo, making it difficult to observe differences at fecal level. Different results could also indicate that 263 
the influence on the microbial generation of SCFA depends on the PC source.  264 
The second mechanism analyzed was the insolubilization of gut cholesterol by its transformation into non-265 
soluble metabolites by gut microbiota. Gut bacteria are able to metabolize cholesterol by two pathways [11]. One 266 
of them transforms cholesterol directly in coprostanol. The other, implies the transformation of cholesterol to 267 
cholestanone, coprostanone and finally coprostanol. Few studies have investigated this gut microbiota-mediated 268 
blood cholesterol lowering mechanism after dietary interventions with PC [42], most of them focusing on 269 
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changes in total fecal cholesterol or total fecal lipids. In our study fecal concentrations of cholesterol remained 270 
constant with the dietary interventions besides the increase in coprostanone observed with FVOO. This could be 271 
due to the fact that we performed fecal analysis in the whole fecal residue, containing bacteria that could be also 272 
either assimilating cholesterol or including it in the bacterial cell wall or both. The absence of any impact on 273 
fecal cholesterol could be also related to the PC source. Whereas PC sources such as horseradish [42], apple skin 274 
[43] and sesame flour [44] have been shown to increase fecal cholesterol in murine models, other sources such as 275 
peanut skin [45] or oolong tea [46] decreased or have no effect on fecal cholesterol levels.  276 
The third mechanism studied was the increase in liver cholesterol expenditure due to microbial generation of 277 
insoluble bile acids in the gut. Bile acids are synthesized in the liver from cholesterol, conjugated and excreted to 278 
the biliary system. From them, 200 to 800 mg/day passes to the colon. Probiotic bacteria, such as bifidobacteria, 279 
encode bile salt hydrolase (BSH) enzymes, which deconjugate bile salts [47]. Deconjugated bile acids are not 280 
absorbed and are excreted in faeces. As synthesis of new bile acids rises in compensation, blood cholesterol 281 
levels fall [14]. In our study, fecal concentrations of primary bile acids did not change with any of the 282 
interventions. This is in concurrence with other authors [48] who were not able to detect any effect of black tea 283 
PC on fecal bile acids in humans. Other PC sources such as peanuts, hazelnut skin and sesame flour [44, 49] 284 
have shown increases in bile acid excretion in murine models. Different sources of PC would have a different 285 
effect on BSH producing bacteria. In our study, the increase in populations of bifidobacteria with FVOOT, 286 
although significant, could have been not enough to significantly increase in the concentrations of deconjugated 287 
bile acids. A novel bile acid-related mechanism has been published recently [50], which suggest that 288 
Lactobacillus, could reduce blood cholesterol by lowering absorption of fat from the intestine via FXR activation 289 
by deconjugated bile acids absorbed from the intestine. Nevertheless, in the present work no decrease in the 290 
systemic cholesterol has been observed and further studies are needed to elucidate the mechanisms and their 291 
degree of involvement. 292 
Besides the absence of changes in the amounts of fecal bile acids, we found a potential detoxificating effect of 293 
FVOO, which reduced the relative proportions of the toxic isolithocholic acid. Deconjugated forms are the 294 
substrate for 7-dehydroxylation, which generates toxic secondary bile acids. Consumption of common dietary 295 
polyphenols has shown to reduce toxic fecal deoxycholic acid and lithocholic acids in rats [51]. Probiotic 296 
bacteria are not capable of dehydroxylate deconjugated bile salts [52], and so the majority of the breakdown 297 
products of BSH activity by a probiotic strain may be precipitated and excreted in feces. Only certain strains of 298 
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Clostridium and Eubacterium spp. have been shown to possess dehydroxylating activity [53]. In our study, the 299 
decrease in the relative proportions of isolithocholic acid could be related to the decrease in populations of 300 
Clostridium cluster IX observed.  301 
The last mechanism investigated in the present study was related to the microbial generation of bioactive PC 302 
metabolites in the gut. It has been demonstrated that bioactivity of some microbial metabolites from undigested 303 
phenolic compounds is physiologically more relevant on CVD risk than the native form present in the diet. Some 304 
representative examples are enterolignans from lignans [54] and protocatechuic acid (PCA) from flavonoids 305 
[55]. PCA promotes reverse cholesterol transport in mice [56] and inhibits LDL oxidation [57] suggesting a 306 
remarkable anti-atherogenic effect. These and other microbial phenolic metabolites with anti-oxidant activity, 307 
such as hydroxytyrosol, generated after gut microbial fermentation of phenolic compounds ingested with the oils 308 
can be further absorbed and enter into the blood stream.  In our study, fecal PCA increased in FVOOT compared 309 
to VOO, which could be due to the microbial transformation of PCA precursors, vanillic and p-hydroxybenzoic 310 
acids, present in FVOOT and absent in VOO. We found also increase in hydroxytyrosol after FVOO and 311 
FVOOT, which could be due to microbial transformation of OO seicoiridoids, and demonstrates a high stability 312 
of hydroxytyrosol in the gut, which is considered to have the highest antioxidant power compared to other olive 313 
polyphenols [58]. The increase in the levels of free hydroxytyrosol in feces after FVOO and FVOOT ingestion 314 
confirms early observations suggesting that a fraction goes via feces [59] and recent observations in a parallel in 315 
vivo trial [15]. In this regard, although the increase in hydroxytyrosol with FVOOT did not reach statistical 316 
significance, it could be behind, in combination with the increase in PCA, the decrease in LDL oxidation 317 
observed after the FVOOT intervention.  318 
 319 
Although effects on gut microbiota and ox-LDL were observed with the combination of both sources of PC 320 
(olive oil and thyme, FVOOT), it is not clear the relevance of each PC source in the results obtained. The lack of 321 
effects observed in FVOO would not necessary mean that these PC are not able to exert an effect on gut 322 
microbiota growth and metabolism. It would be probably due to the high amount used (500 ppm in FVOO 323 
compared to 250 ppm in FVOOT), which could exert an inhibitory effect on gut microbiota growth and 324 
metabolism. Furthermore, another advantage of the combination of both PC sources is that the pro-oxidant 325 
activity observed in with PC-rich foods containing unique PC sources could be eliminated with the use of 326 
complementary PC sources; a functional oil with complementary antioxidants (FVOOT), according to their 327 
14 
 
structure/activity relationship, could be a suitable option to obtain PC’s beneficial effects avoiding these harmful 328 
ones [60]. 329 
In conclusion, the ingestion of a PC-enriched virgin olive oil, containing a mixture of olive oil and thyme PC for 330 
three weeks, decreases blood ox-LDL in hypercholesterolemic humans. This cardio-protective effect could be 331 
mediated by the increases in populations of bifidobacteria together with increases in anti-oxidant PC microbial 332 
metabolites such as protocatechuic acid and hydroxytyrosol. The specific growth stimulation of bifidobacteria in 333 
human gut suggests for first time a potential prebiotic activity of an olive oil enriched in virgin olive oil and 334 
thyme PC.  335 
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VOO FVOO FVOOT 
PHENOLIC COMPOUNDS (mg/25 mL)      
hydroxytyrosol 0.01 ± 0.00 0.21 ± 0.02 0.12 ± 0.00 
3,4-DHPEA-AC
c)
 n.d.  0.84 ± 0.06 0.39 ± 0.04 
3,4-DHPEA-EDA 0.04 ± 0.00 6.73 ± 0.37 3.43 ± 0.29 
3,4-DHPEA-EA 0.26 ± 0.04 0.71 ± 0.06 0.36 ± 0.03 
Total hydroxytyrosol derivates 0.30  8.49  4.30  
p-hydroxybenzoic acid n.d.  0.02 ± 0.00 0.06 ± 0.00 
vanillic acid n.d.  0.07 ± 0.00 0.13 ± 0.01 
caffeic acid n.d.  0.00 ± 0.00 0.06 ± 0.00 
rosmarinic acid n.d.  n.d.  0.41 ± 0.03 
Total phenolic acids -  0.09  0.65  
thymol n.d.  n.d.  0.64 ± 0.05 
carvacrol n.d.  n.d.  0.23 ± 0.02 
Total monoterpenes -  -  0.86  
luteolin 0.04 ± 0.00 0.18 ± 0.02 0.21 ± 0.02 
apigenin 0.02 ± 0.00 0.06 ± 0.00 0.10 ± 0.00 
naringenin n.d.  n.d.  0.20 ± 0.02 
eriodictyol n.d.  n.d.  0.17 ± 0.01 
thymusin n.d.  n.d.  1.22 ± 0.09 
xanthomicrol n.d.  n.d.  0.53 ± 0.06 
7-methylsudachitin n.d.  n.d.  0.53 ± 0.09 
Total flavonoids 0.06  0.23  2.95  
pinoresinol 0.05 ± 0.00 0.12  ± 0.00 0.10 ± 0.05 
acetoxipinoresinol 2.47 ± 0.19 3.66  ± 0.31 3.24 ± 0.28 
Total lignans 2.52  3.78  3.34  
     
FAT SOLUBLE MICRONUTRIENTS (mg/25 mL)     
α-tocopherol 3.27 ± 0.01 3.40 ± 0.02 3.44 ± 0.01 
lutein 0.05 ± 0.00 0.06 ± 0.00 0.06 ± 0.00 
β-cryptoxanthin 0.02 ± 0.00 0.03 ± 0.00 0.02 ± 0.00 
β-carotene 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
       
FATTY ACIDS (relative area %)     
Palmitic acid  11.21  11.20  11.21  
Stearic acid 1.92  1.92  1.92  
Araquidic acid  0.36  0.36  0.36  
Behenic acid   0.11  0.11  0.11  
Total saturated 13.75  13.74  13.75  
Palmitoleic acid 0.70  0.70  0.69  
Oleic acid 76.74  76.83  76.75  
Gadoleic acid 0.27  0.27  0.27  
Total monounsaturated 77.71  77.80  77.72  
Linoleic acid 7.43  7.36  7.43  
Timnodonic acid 0.36  0.36  0.35  
Linolenic acid 0.43  0.43  0.43  
Total polyunsaturated 8.22  8.15  8.22  
22 
 
PC and fat-soluble micronutrients are expressed as means ± SD of mg in 25 mL oil/day. The acidic composition is expressed 
as relative area percentage 
a VOO, 80 mg/kg of phenolic compounds (PC) from olive oil; FVOO, 500mg/kg of PC from olive oil; FVOOT, 250 mg/kg of 
PC from olive oil and 250 mg/kg from thyme. 
b 3,4-DHPEA-AC, 4-(acetoxyethyl)-1,2-dihydroxybenzene; 3,4-DHPEA-EDA, dialdehydic form of elenolic acid linked to 
hydroxytyrosol; 3,4-DHPEA-EA, oleuropein aglycone 







































Values are given as adjusted means of log10 bacteria/g dry feces  ± SE; n=12 subjects.
 
a
 VOO, 80 mg/kg of phenolic compounds (PC) from olive oil; FVOO, 500mg/kg of PC from olive oil; FVOOT, 250 mg/kg of PC from olive oil and 250 mg/kg from thyme. 
b















        
Ato291 B 8.80±0.09 8.86±0.11 8.72±0.10    
 A 8.78±0.09 8.64±0.09 8.72±0.09 0.319 0.947 0.293 
        
Bac303 B 8.68±0.38 8.87±0.42 8.64±0.40    
 A 8.75±0.39 8.73±0.39 8.73±0.40 0.423 0.917 0.373 
        
Bif164 B 8.33±0.25 8.29±0.27 8.14±0.26    
 A 8.10±0.25 8.11±0.26 8.32±0.26 0.818 0.044 0.073 
        
Fprau645 B 8.90±0.06 9.03±0.07 8.96±0.06    
 A 8.90±0.06 8.92±0.06 8.93±0.06 0.420 0.831 0.558 
        
Lab158 B 8.30±0.20 8.43±0.22 8.24±0.21    
 A 8.44±0.20 8.32±0.21 8.27±0.21 0.145 0.512 0.427 
        
Prop853 B 8.81±0.08 8.99±0.10 8.81±0.09    
 A 8.98±0.08 8.79±0.08 8.80±0.08 0.066 0.338 0.364 
        
Rrec584 B 8.74±0.08 8.81±0.10 8.63±0.09    
 A 8.76±0.09 8.61±0.09 8.79±0.09 0.303 0.461 0.085 
24 
 
Table 3  Short chain fatty acids , neutral sterols and bile acids determined in fecal samples collected before (B) 
and after (A) each olive oil intervention
a
 
Values are given as adjusted means and CI; n=12. 
a25 mL/day extra virgin olive oil containing: VOO, 80 mg/kg of phenolic compounds (PC) from olive oil; FVOO, 500mg/kg 
of PC from olive oil; FVOOT, 250 mg/kg of PC from olive oil and 250 mg/kg from thyme. 
b df, dry feces. 
c Sum of isobutyric, isovaleric and valeric acids. 
d P values for inter dietary intervention comparisons. 
  Olive oil interventions  P
d
 









(µmol/g  df 
b
) 
       
Acetic B 195.11 (102.26,372.27) 144.12 (73.80,281.43) 147.96 (80.50,271.96)    
 A 177.99 (94.02,336.97) 168.07 (94.50,298.93) 159.71 (74.71,341.41) 0.364 0.547 0.772 
        
Butyric B 64.25 (26.24,157.34) 42.40 (19.70,91.28 ) 44.38 (21.08,93.46)    
 A 57.97 (22.23,151.15) 52.64 (25.45,108.87) 42.27 (16.79,106.42) 0.264 0.854 0.347 
        
Propionic B 62.88 (32.56,121.45) 48.50 (24.03,97.87) 47.99 (23.89,96.39)    
 A 50.84 (26.72,96.71) 51.68 (26.89,99.32) 48.63 (21.00,112.64) 0.333 0.444 0.858 
        
Branched
c
 B 28.18 (14.70,54.02) 25.78 (16.76,39.66) 25.26 (14.85,42.97)    
 A 24.63 (14.22,42.66) 29.95 (17.71,50.63) 23.42 (15.05,36.43) 0.117 0.751 0.207 
Neutral sterols 
(µmol/g  df ) 
       
Cholesterol B 4.18 (2.06,8.50) 2.17(0.29 16.05) 4.57 (1.72, 12.17)    
 A 3.61 (1.28,10.21) 3.33 (0.72, 15.44) 3.53 (1.28, 9.73) 0.176 0.798 0.103 
        
Coprostanol B 89.04 (38.77,204.48) 79.63 (17.92, 353.95) 109.58 (42.07, 285.43)    
 A 73.99 (26.96, 203.11) 111.49 (29.37, 
423.25) 
116.42 (38.99, 347.59) 0.266 0.622 0.559 
        
Cholestanone B 0.21 (0.01, 6.99) 0.07 (0.01, 0.33) 0.17 (0.02, 1.74)    
 A 0.28 (0.01, 6.74) 0.11 (0.03, 0.35) 0.21 (0.03, 1.37) 0.723 0.904 0.631 
        
Coprostanone B 0.73 (0.25, 2.16) 0.39 (0.04, 4.03) 1.02 (0.25, 4.12)    




(mmol/10 g df) 
       
Cheno-
deoxycholic 
B 2.42 (0.14, 40.84) 2.39 (0.37, 15.29) 1.68 (0.18, 15.52)    
 A 2.78 (0.23, 33.32) 4.54 (0.99, 20.93) 1.55 (0.34, 7.15) 0.493 0.776 0.319 
        
Cholic  B 1.10 (0.16, 7.68) 0.65 (0.14, 3.05) 0.64 (0.09, 4.35)    
 A 1.22 (0.24, 6.18) 1.46 (0.27, 7.76) 0.99 (0.17, 6.00) 0.356 0.666 0.621 
        
Lithocholic  B 9.07 (1.73, 47.69) 11.00 (2.15, 56.20) 8.67 (1.47, 51.06)    
 A 9.81 (3.21, 30.02) 19.01 (7.09, 51.00) 11.58 (4.05, 33.14) 0.407 0.721 0.644 
        
Isolithocholic B 2.34 (0.52, 10.50) 3.98 (0.72, 21.90) 2.10 (0.25, 17.79)    
 A 2.17 (0.48, 9.81) 3.42 (1.18, 9.89) 2.80 (0.90, 8.79) 0.895 0.556 0.450 
        
Deoxycholic  B 32.82 (11.37, 94.72) 34.37 (11.96, 98.75) 27.87 (3.37, 230.44)    
 A 39.97 (11.44,139.66) 54.67 (20.03, 149.23) 48.17 (8.15, 284.76) 0.604 0.519 0.870 
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Table 4 Phenolic metabolites determined by LC in fecal samples collected before (B) and after (A) each olive oil 
intervention
a 
Values are given as adjusted means of µmol/100g dry feces and CI; n=12 subjects.
 
a 
VOO, 80 mg/kg of phenolic compounds (PC) from olive oil; FVOO, 500mg/kg of PC from olive oil; FVOOT, 250 
mg/kg of PC from olive oil and 250 mg/kg from thyme. 
b
P values for inter dietary intervention comparisons. 
c 
M1: unknown metabolite. (M-H)
- 
= 187 m/z. MS
2





 fragments = 227, 207, 119 m/z  
*0.05<P<0.1;**P≤0.05 for intra dietary intervention differences.
Phenolic  
metabolite  







Hydroxytyrosol B 0.19 (0.02, 2.28) 0.15 ( 0.02, 1.13) 0.08 (0.01, 1.16)    
 A 0.16 (0.02, 1.50) 0.74( 0.10, 5.76)** 0.33 (0.01, 10.30)* 0.108 0.140 0.928 
        
Dihydroxyphenyl- 
acetic acid 
B 46.60 (39.05, 55.62) 30.07 (25.32, 35.72) 30.54 (25.29, 36.88)    
A 23.25 (19.10, 28.30)** 40.93 (34.43, 48.66) 30.64 (25.53, 36.77) 0.014 0.092 0.435 
        
Hydroxyphenylacetic 
acid 
B 31.82 (24.61, 41.14) 18.67 (14.58, 23.92) 23.75 (17.93, 31.47)    
A 14.32 (10.54, 19.45)* 17.95 (14.00, 23.03) 28.75 (21.98, 37.60) 0.226 0.129 0.708 
        
Phenylacetic acid 
 
B 248.64 (235.64, 262.35) 234.06 (222.17, 246.58) 232.18 (219.18, 245.96)    
A 206.00 (193.89, 218.86) 262.72 (249.31, 276.86) 203.29 (192.30, 214.91) 0.194 0.818 0.281 
        
Dihydroxyphenyl-
propionic acid 
B 0.01 (0.00, 0.02) 0.00 (0.00, 0.01) 0.00 (0.00, 0.02)    
A 0.01 (0.00, 0.05) 0.00 (0.00, 0.01) 0.01 (0.00, 0.02) 0.690 0.617 0.913 
        
Hydroxyphenyl-
propionic acid 
B 102.51 (56.87, 184.78) 42.20 (23.18, 76.82) 36.80 (19.52, 69.37)    
A 65.56 (33.44, 128.56) 33.07 (18.61, 58.75) 39.08 (21.19, 72.07) 0.796 0.534 0.703 
        
Phenylpropionic acid B 165.40 (148.88, 183.75) 122.41 (110.50, 135.60) 127.89 (114.30, 143.11)    
A 143.23 (127.36, 161.09) 138.01 (124.51, 152.97) 117.83 (105.70, 131.35) 0.394 0.847 0.510 
        
Rosmarinic acid 
 
B 2.60 (1.40, 4.83) 1.80 (1.01, 3.23) 2.76 (1.57, 4.87)    
A 2.83 (1.41, 5.68) 1.85 (1.13, 3.04) 2.22 (1.29, 3.82) 0.938 0.684 0.733 
        
Protocatechuic acid B 0.55 (0.03, 9.15) 0.11 (0.00, 3.01) 0.07 (0.00, 1.45)    
 A 0.04 (0.00, 0.683)** 0,11 (0.00, 3.41) 0.10 (0.01, 1.80) 0.008 0.003 0.652 
        
Coumaric sulfate acid B 2.92 (1.74, 4.89) 3.96 (2.40, 6.53) 2.93 (1.64, 5.24)    
A 1.50 (0.83, 2.70) 4.46 (2.70, 7.37) 3.81 (2.22, 6.54) 0.288 0.231 0.842 
        
Caffeic acid  B 1.94 (1.68, 2.24) 2.18 (1.89, 2.51) 2.41 (2.07, 2.81)    
 A 2.74 (2.35, 3.19) 2.68 (2.32, 3.09) 2.16 (1.87, 2.49) 0.247 0.597 0.110 
        
Ferulic acid 
 
B 1.01 (0.61, 1.67) 0.58 (0.40, 0.85) 0.89 (0.52, 1.52)    
A 1.81 (1.10, 2.97) 0.93 (0.65, 1.31) 1.30 (0.81, 2.09) 0.881 0.817 0.924 
        
Hydroxyphenyl-
valerolactone 
B 2.52 (1.77, 3.60) 4.94 (3.48, 7.00) 3.93 (2.55, 6.06)    
A 3.61 (2.32, 5.63) 3.42 (2.41, 4.84) 7.80 (5.39,11.28) 0.401 0.718 0.231 
        
M1c) B 141.53 (104.14, 192.33) 105.88 (78.05, 143.62) 126.55 (92.70, 172.76)    
 A 106.46 (77.81, 145.67) 134.85 (99.37, 183.01) 126.66 (93.00, 172.51) 0.027 0.236 0.295 
        
M2 B 1.61 (1.18, 2.20) 1.00 (0.73, 1.37) 1.40 (1.01, 1.95)    
 A 0.88 (0.63, 1.25)* 1.50 (1.11, 2.04) 1.58 (1.15, 2.18) 0.042 0.152 0.559 
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